| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2016 ( Subtotal = $0 ) |
| | 2016 | 2013 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R01FD003715 | Phase 3 Study of PTC124 in Cystic Fibrosis (IND 48,648) | 000 | 4 | FDA | 3/15/2016 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = -$395,391 ) |
| | 2015 | 2010 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080-2400 | MIDDLESEX | USA | R01FD003713 | Phase 2 Study of PTC299 in Glioblastoma Multiforme (IND 71,033) | 000 | 1 | FDA | 12/29/2014 | -$395,391 |
|
| Issue Date FY: 2014 ( Subtotal = $0 ) |
| | 2014 | 2013 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R01FD003715 | Phase 3 Study of PTC124 in Cystic Fibrosis (IND 48,648) | 000 | 4 | FDA | 5/9/2014 | $0 |
|
| Issue Date FY: 2013 ( Subtotal = $399,984 ) |
| | 2013 | 2013 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080-2400 | MIDDLESEX | USA | R01FD003715 | Phase 3 Study of PTC124 in Cystic Fibrosis (IND 48,648) | 000 | 4 | FDA | 9/4/2013 | $399,984 |
| | 2013 | 2012 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R01FD003543 | PHASE 2B STUDY OF PTC124 IN DUCHENNE/BECKER MUSCULAR DYSTROPHY (IND 68,431) | 000 | 4 | FDA | 5/8/2013 | $0 |
| | 2013 | 2010 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R01FD003713 | Phase 2 Study of PTC299 in Glioblastoma Multiforme (IND 71,033) | 001 | 1 | FDA | 8/30/2013 | $0 |
| | 2013 | 2010 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R01FD003713 | Phase 2 Study of PTC299 in Glioblastoma Multiforme (IND 71,033) | 000 | 1 | FDA | 10/24/2012 | $0 |
| | 2013 | 2007 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R01FD003009 | PTC124 AS A THERAPY FOR NON-SENSE MUTATION MEDIATED CYSTIC FIBROSIS | 001 | 2 | FDA | 5/16/2013 | $0 |
| | 2013 | 2007 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R01FD003110 | PHASE 2 STUDY OF PTC124 AS AN ORAL TREATMENT FOR NONSEN* | 000 | 2 | FDA | 5/16/2013 | $0 |
| | 2013 | 2006 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R01FD003009 | PTC124 AS A THERAPY FOR NON-SENSE MUTATION MEDIATED CYSTIC FIBROSIS | 000 | 2 | FDA | 5/16/2013 | $0 |
|
| Issue Date FY: 2012 ( Subtotal = $1,880,702 ) |
| | 2012 | 2012 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080-2400 | MIDDLESEX | USA | R01FD003715 | Phase 3 Study of PTC124 in Cystic Fibrosis (IND 48,648) | 000 | 3 | FDA | 9/7/2012 | $399,984 |
| | 2012 | 2012 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080-2400 | MIDDLESEX | USA | R01FD003543 | PHASE 2B STUDY OF PTC124 IN DUCHENNE/BECKER MUSCULAR DYSTROPHY (IND 68,431) | 000 | 4 | FDA | 1/31/2012 | $398,393 |
| | 2012 | 2012 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080-2400 | MIDDLESEX | USA | R56AI098837 | DISCOVERY OF ANTIVIRAL AGENTS TARGETING DENGUE VIRAL TRANSLATION | 000 | 1 | NIH | 9/7/2012 | $1,082,325 |
| | 2012 | 2010 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R01FD003713 | Phase 2 Study of PTC299 in Glioblastoma Multiforme (IND 71,033) | 000 | 1 | FDA | 8/31/2012 | $0 |
|
| Issue Date FY: 2011 ( Subtotal = $798,377 ) |
| | 2011 | 2011 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080-2400 | MIDDLESEX | USA | R01FD003715 | Phase 3 Study of PTC124 in Cystic Fibrosis (IND 48,648) | 002 | 2 | FDA | 8/24/2011 | $399,984 |
| | 2011 | 2011 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080-2400 | MIDDLESEX | USA | R01FD003543 | PHASE 2B STUDY OF PTC124 IN DUCHENNE/BECKER MUSCULAR DYSTROPHY (IND 68,431) | 001 | 3 | FDA | 2/4/2011 | $398,393 |
| | 2011 | 2010 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R01FD003713 | Phase 2 Study of PTC299 in Glioblastoma Multiforme (IND 71,033) | 002 | 1 | FDA | 9/2/2011 | $0 |
| | 2011 | 2010 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R01FD003713 | Phase 2 Study of PTC299 in Glioblastoma Multiforme (IND 71,033) | 000 | 1 | FDA | 10/27/2010 | $0 |
| | 2011 | 2010 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R01FD003543 | PHASE 2B STUDY OF PTC124 IN DUCHENNE/BECKER MUSCULAR DYSTROPHY (IND 68,431) | 000 | 2 | FDA | 10/27/2010 | $0 |
| | 2011 | 2010 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R01FD003715 | Phase 3 Study of PTC124 in Cystic Fibrosis (IND 48,648) | 000 | 1 | FDA | 10/27/2010 | $0 |
| | 2011 | 2010 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R01FD003715 | Phase 3 Study of PTC124 in Cystic Fibrosis (IND 48,648) | 001 | 1 | FDA | 6/23/2011 | $0 |
| | 2011 | 2010 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R01FD003713 | Phase 2 Study of PTC299 in Glioblastoma Multiforme (IND 71,033) | 001 | 1 | FDA | 2/22/2011 | $0 |
|
| Issue Date FY: 2010 ( Subtotal = $1,696,334 ) |
| | 2010 | 2010 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | RC1HL100159 | PHASE 2A STUDY OF ATALUREN IN HEMOPHILIA A AND B (IND 104,321) | 002 | 2 | NIH | 9/7/2010 | $0 |
| | 2010 | 2010 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080-2400 | MIDDLESEX | USA | R01FD003543 | PHASE 2B STUDY OF PTC124 IN DUCHENNE/BECKER MUSCULAR DYSTROPHY (IND 68,431) | 000 | 2 | FDA | 2/22/2010 | $398,393 |
| | 2010 | 2010 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080-2400 | MIDDLESEX | USA | R01FD003715 | Phase 3 Study of PTC124 in Cystic Fibrosis (IND 48,648) | 000 | 1 | FDA | 9/1/2010 | $399,984 |
| | 2010 | 2010 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080-2400 | MIDDLESEX | USA | R01FD003713 | Phase 2 Study of PTC299 in Glioblastoma Multiforme (IND 71,033) | 000 | 1 | FDA | 9/10/2010 | $399,742 |
| | 2010 | 2010 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080-2400 | MIDDLESEX | USA | RC1HL100159 | PHASE 2A STUDY OF ATALUREN IN HEMOPHILIA A AND B (IND 104,321) | 001 | 2 | NIH | 8/27/2010 | $498,215 |
| | 2010 | 2009 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | RC1HL100159 | PHASE 2A STUDY OF ATALUREN IN HEMOPHILIA A AND B (IND 104,321) | 000 | 1 | NIH | 2/24/2010 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $896,608 ) |
| | 2009 | 2009 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080-2400 | MIDDLESEX | USA | R01FD003543 | PHASE 2B STUDY OF PTC124 IN DUCHENNE/BECKER MUSCULAR DYSTROPHY (IND 68,431) | 000 | 1 | FDA | 2/12/2009 | $398,393 |
| | 2009 | 2009 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080-2400 | MIDDLESEX | USA | RC1HL100159 | PHASE 2A STUDY OF ATALUREN IN HEMOPHILIA A AND B (IND 104,321) | 000 | 1 | NIH | 9/24/2009 | $498,215 |
|
| Issue Date FY: 2007 ( Subtotal = $791,628 ) |
| | 2007 | 2007 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R42HD048137 | MECHANISM OF NONSENSE MUTATION SUPPRESSION THERAPY | 000 | 3 | NIH | 4/5/2007 | $444,298 |
| | 2007 | 2007 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R01FD003009 | PTC124 AS A THERAPY FOR NON-SENSE MUTATION MEDIATED CYSTIC FIBROSIS | 001 | 2 | FDA | 9/20/2007 | $68,105 |
| | 2007 | 2007 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R01FD003110 | PHASE 2 STUDY OF PTC124 AS AN ORAL TREATMENT FOR NONSEN* | 000 | 2 | FDA | 8/31/2007 | $279,225 |
|
| Issue Date FY: 2006 ( Subtotal = $1,862,441 ) |
| | 2006 | 2006 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | 1R01FD003110 | Phase 2 Study of PTC 124 | 01 | 01 | FDA | 9/20/2006 | $279,225 |
| | 2006 | 2006 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | 5R01 FD003009 | PTC124 as a Therapy for Nonsense-Mutation-Medicated CF | 01 | 02 | FDA | 9/20/2006 | $478,398 |
| | 2006 | 2006 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R44CA108330 | DEVELOPMENT OF AN INHIBITOR OF VEGF EXPRESSION | 000 | 3 | NIH | 9/18/2006 | $740,577 |
| | 2006 | 2006 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 07080 | MIDDLESEX | USA | R42HD048137 | MECHANISM OF NONSENSE MUTATION SUPPRESSION THERAPY | 000 | 2 | NIH | 5/16/2006 | $364,241 |
|
| Issue Date FY: 2005 ( Subtotal = $1,770,416 ) (Continued on the next page) |
| | 2005 | 2005 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 01519 | | USA | R41AI060510 | A NOVEL HIV-1 LATENCY SYSTEM FOR DRUG DISCOVERY | 000 | 1 | NIH | 3/23/2005 | $100,000 |
| | 2005 | 2005 | PTC THERAPEUTICS INC | 100 CORPORATE COURT MIDDLESEX | SOUTH PLAINFIELD | NJ | 01519 | | USA | R44AI054029 | DEVELOPING ANTIVIRAL AGENTS THAT INHIBIT HCV TRANSLATION | 000 | 3 | NIH | 3/29/2005 | $652,409 |
|
